title: Expression of OV-6 in primary colorectal cancer and rectal cancer with preoperative chemoradiotherapy: a clinicopathological study.
abstract: OBJECTIVE
  OV-6 is among the best available markers of liver stem cells. The aim of this study was to investigate OV-6 expression and its clinical implications in colorectal cancer.
  
  
  RESULTS
  Expression of OV-6 and its clinical implications were investigated in 94 patients with American Joint Committee on Cancer (AJCC) stage I-III primary colorectal cancer and in 37 rectal cancer patients who had received preoperative chemoradiotherapy. The two main expression patterns of OV-6 were cytoplasmic and membranous. Overexpression of OV-6, which was identified on the basis of overall staining intensity, was associated with perineural invasion, lymphovascular invasion, and early relapses. Membranous OV-6 overexpression was also significantly associated with depth of tumour invasion, AJCC stage, lymphovascular and perineural invasion, and postoperative early relapse. Disease-free survival and overall survival were significantly poorer in patients with high overall OV-6 expression than in those with low overall OV-6 expression (P = 0.015 and P = 0.029, respectively), and significantly poorer in patients with high membranous OV-6 expression than in those with low membranous OV-6 expression (P < 0.001 and P < 0.001, respectively). Membranous OV-6 expression was a more reliable prognostic marker than overall expression.
  
  
  CONCLUSIONS
  OV-6 is not unique to the hepatobiliary system, and may be a novel prognostic marker in colorectal cancer.
authors: Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
authors: Chih-Hung
authors: CH
authors: Lin
authors: Chia-Hsing
authors: CH
authors: Liu
authors: Hsiang-Lin
authors: HL
authors: Tsai
authors: Jaw-Yuan
authors: JY
authors: Wang
authors: Hung-Pei
authors: HP
authors: Tsai
authors: Chee-Yin
authors: CY
authors: Chai
mesh_terms: D000368:Aged; D000943:Antigens, Differentiation / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D059186:Chemoradiotherapy, Adjuvant / Q000379:methods*; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009367:Neoplasm Staging; D012004:Rectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate; D013624:Taiwan / Q000453:epidemiology
chemical_list: D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor; C115011:oval cell marker OV-6